| Literature DB >> 23690831 |
Waris Qidwai1, Tabinda Ashfaq.
Abstract
Introduction. Rapidly growing prevalence of cardiovascular disease is a major threat for the developed as well as developing world warranting urgent need of intervention. Complementary and alternative medicines are gaining popularity among general population because of their safety profile and easy administration. Garlic, in particular, is considered to be one of the best disease-preventive foods because of its potent and widespread effects. This study was done to find out the role of garlic usage in cardiovascular disease prevention. Methodology. Major databases including Google, PubMed, MEDLINE, and Cochrane library view were used for the literature search. Clinical trials conducted on humans assessing role of garlic usage in cardiovascular disease prevention and the possible mechanisms responsible for such therapeutic actions were assessed. Results. Various clinical trials and meta-analyses conducted have shown positive impact of garlic in cardiovascular-disease prevention especially its effects on lipid levels; however, some contradictory results are also reported. Similarly, its effects on hypertension control, and platelet are also mild with limited data availability. The possible reason for these inconsistent results is the difference in preparations with diverse composition, variations in sulphur content present in different garlic preparations used, and methodological variations in subject recruitment, duration of study, dietary control and so forth. Conclusion. Garlic can be used as an adjuvant with lipid-lowering drugs for control of lipids, however, its role as a main therapeutic agent cannot be recommended and it is suggested that more meta-analyses using standardized preparations with a close watch on methodological shortfalls should be conducted to prove its role.Entities:
Year: 2013 PMID: 23690831 PMCID: PMC3652202 DOI: 10.1155/2013/125649
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Effects of garlic on lipid levels.
| Study | Type | Target | Duration of Rx | Dose | Case/control | Outcome |
|---|---|---|---|---|---|---|
| Mader, (1990) [ | Randomized, placebo-controlled trial | Hyperlipidemic | 12 weeks | 800 mg garlic powder | 130/131 | Dec in T. chol level—12%, TG level—17% |
|
| ||||||
| Gadkari and Joshi, (1991) [ | Randomized control trial | Normal individuals | 2 months | 10 gm of raw garlic | 25/25 | Dec T. chol, increase clotting time, and fibrinolytic activity |
|
| ||||||
| Rotzsch et al., (1992) [ | Randomized, placebo-controlled, double-blind trial | Healthy individuals with low HDL | 6 weeks | 900 mg garlic powder | 12/12 | Dec TG levels and increase HDL levels |
|
| ||||||
| Saradeth et al., (1994) [ | Randomized double-blind study, placebo-controlled trial | Healthy individuals with normal lipid levels | 15 weeks | 600 mg dried garlic powder | 34/34 | T. chol dec from 223 to 214 mg/dL |
|
| ||||||
| Steiner et al., (1996) [ | Double-blind crossover trial | Hyperlipidemic | 11 months | 7.2 g aged garlic | 20/21 | Dec T. chol 6.1%, dec LDL 4%, systolic BP 5.5% dec, and modest dec in diastolic Bp noticed |
|
| ||||||
| Isaacsohn et al., (1998) [ | Randomized, double-blind, placebo-control trial | Hyperlipidemic | 12 weeks | 900 mg garlic powder (Kwai) | 28/22 | No change in lipid levels noticed |
|
| ||||||
| Berthold et al., (1998) [ | Double-blind, randomized, placebo-controlled trial | Hyperlipidemic | 12 weeks | 10 mg garlic oil | 12/13 | No change in lipids or lipoproteins levels noticed |
|
| ||||||
| Satitvipawee et al., (2003) [ | Randomized, double-blind, placebo-controlled trial | Hyperlipidemic | 4 weeks/12 weeks | Garlic extract | 70/76 | No dec in T. chol, DL, TG, and HDL levels noticed |
|
| ||||||
| Mahmoodi et al., (2006) [ | Clinical trial | Hyperlipidemic | 42 days | Raw garlic 5 gm twice daily | 30 | Dec T. chol, dec LDL, dec TG, increase HDL level |
|
| ||||||
| Sobenin et al., (2008) [ | Double blinded placebo controlled | Hyperlipidemic | 12 weeks | Allicor | 21/21 | T. chol 7.6% dec, LDL 11.8%, and HDL inc 11.5% |
T. chol: total cholesterol, HDL: high-density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, and VLDL: very low-density lipoprotein.
Effect of garlic on blood pressure levels.
| Study | Type | Target | Duration of Rx | Dose | Case/control | Outcome |
|---|---|---|---|---|---|---|
| Zhang et al., (2001) [ | Parallel-controlled trial | Hypertensives | 16 weeks | Distilled garlic oil 12.3 mg/d | 14/13 | Garlic oil lowers SBP and DBP |
|
| ||||||
| Dhawan and Jain, (2004) [ | Not placebo controlled | Hypertensives | 2 months | Garlic pearls 250 mg | 20/20 | Dec Bp, dec ox-LDL, and 8-iso-PGF2alpha levels |
|
| ||||||
| Capraz et al., (2007) [ | Randomized placebo control trial | Hypertensives | 70 minutes | Rw garlic, Garlic tablets | 25/25/25 | No effects on BP levels |
|
| ||||||
| Duda et al., (2008) [ | Prospective and uncontrolled clinical study | Hypertensives | 30 days | Antihypertensive drug + Garlic capsules | 38/32 | Dec total lipids and lipid peroxidation noticed |
|
| ||||||
| Ried et al., (2010) [ | Randomized placebo control trial | Hypertensives | 12 weeks | 960 mg AGE | 25/25 | SBP—10.2 ± 4.3 mmHg dec |
|
| ||||||
| Ried et al., (2013) [ | Double-blind, randomized placebo-controlled, dose-response trial | Hypertensives | 12 weeks | Aged garlic 240/480/960 mg | 26/26/27 | SBP—11.8 ± 5.4 mmHg, (2 capsule) 7.4 ± 4.1 mmHg (4 capsule) |
T. chol: total cholesterol, HDL: high density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, VLDL: very low-density lipoprotein, 8-OHdG: (8-Hydroxy-2′-deoxyguanosine), and 8-iso-PGF2alpha: (8-iso-Prostaglandin F2alpha).
Effect of garlic on cardiovascular disease.
| Study | Type | Target | Duration of treatment | Dose | Route | Case/control | Outcome |
|---|---|---|---|---|---|---|---|
| Bordia et al., (1998) [ | Placebo control trial | Coronary artery disease patients | 3 months | 1 gm garlic (capsules) | Oral | 30/30 | Dec T. chol and TG, increase HDL level, and no effect on fibrinogen and glucose level |
|
| |||||||
| Sobenin et al., (2010) [ | Randomized control trial | Coronary artery disease patients | 1 year | Time-released garlic powder | Oral | 26/25 | Dec LDL—32.9 mg/dL in males, 27.3 mg/dL in females |
T. chol: total cholesterol, HDL: high-density lipoprotein, TG triglyceride, LDL: low-density lipoprotein.